Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Retained Earnings (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Retained Earnings for 3 consecutive years, with -$213.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Retained Earnings fell 265.96% to -$213.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$213.4 million, a 265.96% decrease, with the full-year FY2024 number at -$106.1 million, up 82.71% from a year prior.
  • Retained Earnings was -$213.4 million for Q3 2025 at Inhibrx Biosciences, down from -$178.1 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$14.4 million in Q2 2024 to a low of -$613.7 million in Q4 2023.
  • A 3-year average of -$190.5 million and a median of -$149.4 million in 2025 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: soared 82.71% in 2024, then crashed 1136.53% in 2025.
  • Inhibrx Biosciences' Retained Earnings stood at -$613.7 million in 2023, then skyrocketed by 82.71% to -$106.1 million in 2024, then tumbled by 101.03% to -$213.4 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Retained Earnings are -$213.4 million (Q3 2025), -$178.1 million (Q2 2025), and -$149.4 million (Q1 2025).